| Document |
Document Title |
|
JP5274838B2 |
Compounds of formula (I) have been found to be useful as inhibitors of DDAH. The present invention thus provides the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for ...
|
|
JP5277213B2 |
Antibacterial compounds of formula (I) are provided: As well as stereoisomers, pharmaceutically acceptable salts, esters, and prodrugs thereof; pharmaceutical compositions comprising such compounds; treating bacterial infections by the a...
|
|
JP5268982B2 |
To provide a disinfectant which includes olanexidine in such a concentration as to show an effective bactericidal activity, is used for stable disinfection without depositing olanexidine, and is reduced in side effects such as skin irrit...
|
|
JP5266499B2 |
The present invention provides a method represented by Scheme 1: wherein X represents I, Br, Cl, alkylsulfonate, or arylsulfonate; Z represents optionally substituted aryl, heteroaryl or alkenyl; L represents hydrogen or a negative charg...
|
|
JP5260877B2 |
The present invention discloses facially amphiphilic polyaryl and polyarylalkynyl polymers and oligomers of formula (Ia), compositions thereof, preparation thereof and their use as antimicrobial agents and as antidotes for hemorrhagic co...
|
|
JP2013531667A |
The present invention relates to calcium salts of compounds of the general formula (I) wherein X is selected from the group consisting of CH 2 , S, or O; D isOorS; R 8 is hydrogen or alkyl; E is an optionally substituted phenylene group;...
|
|
JP2013528174A |
The present invention includes bis- and tris-benzamide compounds that block AR signaling and have anticancer activity. Uses for these compounds, and pharmaceutical compositions containing the same, also are provided.
|
|
JP5213961B2 |
The amino acid derivative of the present invention provides a novel compound that shows excellent analgesic action. The amino acid derivative of the present invention is a novel compound that shows excellent analgesic action to not only ...
|
|
JP2013523777A |
Disclosed are neuraminidase inhibitor compounds and pharmaceutical compositions with improved bioavailability and/or improved efficacy and methods of treating influenza using the compounds and pharmaceuticals compositions.
|
|
JP5209832B2 |
Derivatives of aryl and heterocyclic ureido and aryl and heterocyclic carboxamido phenoxy isobutyric acids have been found to inhibit the nonenzymatic glycation of proteins which often results in formation of advanced glycation endproduc...
|
|
JP5210405B2 |
|
|
JP5209302B2 |
Compounds useful in modulating angiogenesis and uses thereof in methods of treating or preventing diseases associated with angiogenesis by administering a polycationic compound; and compositions for use in inhibiting angiogenesis-mediate...
|
|
JP2013518897A |
Disclosed herein are substituted fluoromethanes; pharmaceutical compositions comprising a therapeutically effective amount of the same; processes for preparing these fluoromethanes; and methods of using the same in alleviating infection ...
|
|
JP5196448B2 |
|
|
JP2013516470A |
The present invention provides compounds and methods for antagonizing the anticoagulant effect of an anticoagulant agent that is selected from UFH, LMWH, and a heparin/LMWH derivative in a patient comprising administering to the patient ...
|
|
JP2013516461A |
A biguanide derivative compound with N4-N5 substitution, which is represented by Formula 1, or a pharmaceutically acceptable salt thereof, a method of preparing the same, and a pharmaceutical composition containing the same as an active ...
|
|
JP2013514357A |
Methods of producing arginine bicarbonate solutions in very high concentrations including reacting an arginine slurry containing a first portion of arginine with a source of carbon dioxide gas at elevated pressure and temperature, adding...
|
|
JP2013514362A |
A method of producing arginine bicarbonate is provided including reacting an arginine slurry with a source of carbon dioxide gas under elevated temperature and low pressure to form a solution of at least 50% arginine bicarbonate, and rec...
|
|
JP5184887B2 |
The present invention relates to novel intermediates useful for the preparation of novel phenylaminopyrimidine derivatives, novel phenylaminopyrimidine derivatives. Pharmaceutical composition containing the novel phenylaminopyrimidine de...
|
|
JP5180421B2 |
The present invention describes a method for providing creatine to an animal which includes receiving a creatine ester by the animal. The creatine ester is suitable for being modified by the animal to form creatine.
|
|
JP5166022B2 |
The present invention is related to uses of a composition comprising a pharmaceutically active component and a compound according to formula (I), wherein R1 and R2 are each and independently selected from the group comprising alkyl; n is...
|
|
JP5148646B2 |
Novel cycloalkyl compounds useful as inhibitors of potassium channel function (especially inhibitors of the K v l subfamily of voltage gated K + channels, especially inhibitors K v 1.5 which has been linked to the ultra-rapidly activatin...
|
|
JP2013504614A |
Prodrugs of guanfacine with amino acids or short peptides, pharmaceutical compositions containing such prodrugs and a method for providing therapeutic benefit in the treatment of ADHD/ODD (attention deficient hyperactivity disorder and o...
|
|
JP5137168B2 |
The present invention herein provides a combination of stable isotope-labeled aliphatic amino acids, which permits the structural analysis of a high molecular weight protein, in particular, a high molecular weight protein whose molecular...
|
|
JP2013010735A |
To provide a 1, 2, 4-triazole compound capable of introducing a guanidine skeleton to an ordinary amine and even to a bulky secondary amine, in which a steric hindrance is supposed, such as diisopropylamine, and to provide a method for s...
|
|
JP5118502B2 |
Compounds I-III wherein U is CH, O, or S; Z is mono- or di-substituted carbon; R is (CH2)nCO2H, (CH2)nSO3H, (CH2)nPO3H2, (CH2)nNO2, CH(SCH3)3, esters; R1 is H, hydroxyalkyl, aminoalkyl, alkoxyalkyl; RR1 is O; n is 0-4; R2, R3 is H, hydro...
|
|
JP5113978B2 |
As novel salts of monatin, salts with organic amines such as amino acids, aminoalcohols, dipeptide esters, etc. are provided. The salts with amino acids or dipeptide esters can be used as sweeteningmaterials, of which the crystals are st...
|
|
JP5116207B2 |
The invention describes compounds represented by the general formula (I) given below: in which: n is an integer between 1 and 4; R1 and R2 are chosen independently from hydrogen and a methyl group; R3 is chosen independently from a linea...
|
|
JP5103563B2 |
The invention relates to (hetero)arylsulfonylamino based peptidomimetics of formula (I), wherein R1, R2, R3, A, B, D, Q, k and n are defined as disclosed, or a pharmaceutically acceptable salt or ester thereof. Compounds of formula (I) p...
|
|
JP5096165B2 |
There are provided technologies for adsorbing a catalyst metal selectively to an anionic group such as a carboxyl group, thereby forming a metal film on a nonconductive resin selectively, including a palladium complex represented by the ...
|
|
JP2012530764A |
The present invention concerns prodrugs of mexiletine (and mexiletine's active metabolite) with amino acids or peptides and pharmaceutical compositions containing such prodrugs. Methods for providing pain relief, treating arrhythmia, dec...
|
|
JP5086635B2 |
Antibacterial compounds of formula (I) are provided: As well as stereoisomers, pharmaceutically acceptable salts, esters, and prodrugs thereof; pharmaceutical compositions comprising such compounds; treating bacterial infections by the a...
|
|
JP5078993B2 |
The present invention provides a process for producing 1-(3,4-dichlorobenzyl)-5-octylbiguanide or a salt thereof, the process comprising reacting 1-cyano-3-octylguanidine or a salt thereof, with 3,4-dichlorobenzylamine or a salt thereof,...
|
|
JP5071905B2 |
|
|
JP5063860B2 |
Diamidine derivatives of formula (I) and their salts are new. Amidine derivatives of formula (I) and their salts are new. [Image] X : a group of formula (ii) or R 4; Z : -(CH 2) m-; m : 8 - 21; n : 0 or 1; Y : R 3 or a group of formula (...
|
|
JP5057782B2 |
The present invention relates to a method for synthesis of an acrylamide derivative, starting with dissolving a salt of a nucleophilic amine in water to form an aqueous solution and desalting said solution with a base, comprising the fol...
|
|
JP5038725B2 |
The invention relates to biocidal polymers based on guanidine salts characterized in that they are representatives of a number of polyoxyalkylene guanidines and their salts and are a product of a polycondensation of guanidine salts with ...
|
|
JP5037436B2 |
The present invention pertains, at least in part, to novel 9- substituted minocycline compounds. These minocycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasm...
|
|
JP5030587B2 |
The invention relates to compounds having antiviral activity and methods utilising the compounds to treat viral infections.
|
|
JP2012167067A |
To clarify a molecular structure of a metal salen complex exhibiting a pharmacological effect, and to provide a metal salen complex including such a molecular structure, as well as a derivative of the complex.This metal salen complex com...
|
|
JP5016752B2 |
A compound of the formula (I) (I) wherein R<1> is a protecting group for N alpha , R<2> is a protecting group for NG, and R<3> is aryl, and wherein the compound of formula (I) is a trypsin substrate such that trypsin cleaves the O-C sing...
|
|
JP5015781B2 |
This invention relates to novel salts of medicinal disulfides. The compounds include a terminal sulfonate or phosphonate moiety, and have many uses, such as toxicity reducing agents when administered with many antineoplastic agents.
|
|
JP5010713B2 |
|
|
JP5001505B2 |
The present invention relates to novel thiourea derivatives as a modulator for vanilloid receptor (VR) and the pharmaceutical compositions containing the same. As diseases associated with the activity of vanilloid receptor, pain acute pa...
|
|
JP4998258B2 |
The invention relates to a medicament for IBS, which comprises a dual antagonist for 5-HT 2B and 5-HT 7 receptors having selective binding affinities for 5-HT 2B and 5-HT 7 receptors. The pharmaceutical composition of the invention is us...
|
|
JP2012148997A |
To provide a guanidine thiocyanate compact sufficiently preventing solidification without using any anticaking agent over long-term storage.A specific surface area of a molded product of guanidine thiocyanate included in the guanidine th...
|
|
JPWO2010090304A1 |
The subject of the present invention is serotonin 5-HT.5ATo provide excellent therapeutic or prophylactic agents for dementia, schizophrenia, etc. based on the receptor-regulating action. The acylguanidine derivative of the following for...
|
|
JPWO2010090305A1 |
The subject of the present invention is serotonin 5-HT.5ATo provide excellent therapeutic or prophylactic agents for dementia, schizophrenia, etc. based on the receptor-regulating action. The acylguanidine derivative of the following for...
|
|
JP2012517447A |
Provided herein is a method for chemically programmed vaccination. Methods include inducing a covalent-binding polyclonal antibody response in a subject and programming the polyclonal response with a targeting compound.
|
|
JP4980893B2 |
|
